Leukemias, lymphomas, and other hematologic cancers:
Indications for: ASPARLAS
Treatment of acute lymphoblastic leukemia as a component of a multi-agent chemotherapeutic regimen.
Adults and Children:
<1month: not established. Premedicate with acetaminophen, H1 receptor blocker (eg, diphenhydramine), and H2 receptor blocker (eg, famotidine) 30–60mins prior to administration. 1month–21yrs: Give by IV infusion over 1hr. 2500 Units/m2 no more frequently than every 21 days. Dose modifications: see full labeling.
ASPARLAS Contraindications:
History of serious thrombosis, pancreatitis, or hemorrhagic events with prior L-asparaginase therapy. Severe hepatic impairment.
ASPARLAS Warnings/Precautions:
Have resuscitation equipment available and observe patient for 1hr post-dose. Assess serum amylase and/or lipase levels. Discontinue if serious hypersensitivity reactions, thrombotic events, or pancreatitis occur. Evaluate for hemorrhage with coagulation parameters. Evaluate LFTs at least weekly, during and for ≥6 weeks after last dose. Discontinue if serious hepatotoxicity occurs. Pregnancy: exclude status prior to initiation. Advise females of reproductive potential to use effective non-hormonal contraception during and for ≥3 months after the last dose. Nursing mothers: not recommended (during and for 3 months after the last dose).
ASPARLAS Classification:
Asparagine-specific enzyme.
ASPARLAS Interactions:
Antagonizes hormonal contraceptives.
Adverse Reactions:
Elevated transaminases, increased bilirubin, pancreatitis, abnormal clotting, diarrhea, hypersensitivity, embolic/thrombotic events, sepsis, dyspnea, hemorrhages.
Generic Drug Availability:
NO
How Supplied:
Single-dose vial (5mL)—1
